JP2024530495A5 - - Google Patents

Info

Publication number
JP2024530495A5
JP2024530495A5 JP2024507883A JP2024507883A JP2024530495A5 JP 2024530495 A5 JP2024530495 A5 JP 2024530495A5 JP 2024507883 A JP2024507883 A JP 2024507883A JP 2024507883 A JP2024507883 A JP 2024507883A JP 2024530495 A5 JP2024530495 A5 JP 2024530495A5
Authority
JP
Japan
Application number
JP2024507883A
Other languages
Japanese (ja)
Other versions
JPWO2023018237A5 (https=
JP2024530495A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2022/011962 external-priority patent/WO2023018237A1/en
Publication of JP2024530495A publication Critical patent/JP2024530495A/ja
Publication of JPWO2023018237A5 publication Critical patent/JPWO2023018237A5/ja
Publication of JP2024530495A5 publication Critical patent/JP2024530495A5/ja
Pending legal-status Critical Current

Links

JP2024507883A 2021-08-10 2022-08-10 新規plk1分解誘導化合物 Pending JP2024530495A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
KR20210105358 2021-08-10
KR10-2021-0105358 2021-08-10
KR20210106488 2021-08-12
KR10-2021-0106488 2021-08-12
KR10-2021-0117389 2021-09-03
KR20210117389 2021-09-03
KR10-2021-0126757 2021-09-24
KR20210126757 2021-09-24
KR20220008456 2022-01-20
KR10-2022-0008456 2022-01-20
KR20220020996 2022-02-17
KR10-2022-0020996 2022-02-17
KR20220054880 2022-05-03
KR10-2022-0054880 2022-05-03
KR20220075838 2022-06-21
KR10-2022-0075838 2022-06-21
PCT/KR2022/011962 WO2023018237A1 (en) 2021-08-10 2022-08-10 Novel plk1 degradation inducing compound

Publications (3)

Publication Number Publication Date
JP2024530495A JP2024530495A (ja) 2024-08-21
JPWO2023018237A5 JPWO2023018237A5 (https=) 2025-08-13
JP2024530495A5 true JP2024530495A5 (https=) 2025-08-13

Family

ID=85200656

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物
JP2024507883A Pending JP2024530495A (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023514160A Active JP7555156B2 (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023514149A Active JP7555155B2 (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物
JP2024507884A Pending JP2024530195A (ja) 2021-08-10 2022-08-10 新規plk1分解誘導化合物

Country Status (15)

Country Link
US (4) US11939334B2 (https=)
EP (4) EP4157849A4 (https=)
JP (4) JP7555156B2 (https=)
KR (5) KR102604803B1 (https=)
CN (2) CN116322700B (https=)
AU (1) AU2022327025A1 (https=)
CA (1) CA3228601A1 (https=)
CL (1) CL2024000373A1 (https=)
CO (1) CO2024001256A2 (https=)
CR (1) CR20240120A (https=)
EC (1) ECSP24010109A (https=)
IL (1) IL310678A (https=)
MX (1) MX2024001774A (https=)
PE (1) PE20240894A1 (https=)
WO (5) WO2023018236A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
UY39892A (es) 2021-08-10 2023-03-31 Novartis Pharma Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING
CN120603831A (zh) * 2022-11-29 2025-09-05 厄普特拉株式会社 具有增加的刚性的plk1降解诱导化合物
KR20250037591A (ko) * 2023-02-02 2025-03-17 (주) 업테라 신규 plk1 분해 유도 화합물
WO2024188209A1 (zh) * 2023-03-10 2024-09-19 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
KR20260022390A (ko) 2023-06-08 2026-02-19 누릭스 테라퓨틱스 인코포레이티드 Smarca2의 선택적 분해제로서의 이작용성 아진 접합체 및 이의 치료적 용도
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途
WO2025062330A1 (en) 2023-09-20 2025-03-27 Aurigene Oncology Limited Heterocyclic compounds as cbp selective degraders
WO2025125575A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025239662A1 (ko) * 2024-05-13 2025-11-20 (주) 업테라 분해 약물-항체 접합체용 plk1 분해 유도 화합물
CN118724841A (zh) * 2024-06-14 2024-10-01 南通华祥医药科技有限公司 一种n-氨基哌啶二盐酸盐的制备方法
WO2026013577A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1
WO2026013576A1 (en) * 2024-07-10 2026-01-15 Monte Rosa Therapeutics Ag Dihydrouracil derivatives useful for the targeted degradation of vav1
WO2026026773A1 (zh) * 2024-07-29 2026-02-05 杭州胶联生物医药科技有限公司 作为vav1蛋白靶点降解剂的新型取代杂环类化合物
WO2026041138A1 (zh) * 2024-08-22 2026-02-26 武汉人福创新药物研发中心有限公司 作为vav1降解剂的苯并杂环类化合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649324A1 (en) * 2006-04-12 2007-10-25 Jean-Damien Charrier Tetrahydropteridines useful as inhibitors of protein kinases
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008113711A1 (en) * 2007-03-22 2008-09-25 F. Hoffmann-La Roche Ag Substituted pyrimidodiazepines useful as plk1 inhibitors
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016349781A1 (en) * 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
BR112019015484A2 (pt) * 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CN106977584B (zh) 2017-04-19 2019-12-06 吉林大学 靶向泛素化降解plk1和brd4蛋白的化合物及其应用
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CN109879877B (zh) 2019-03-04 2021-08-10 吉林大学 一种可降解plk1和brd4蛋白的化合物及其应用
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
AU2020356484A1 (en) * 2019-09-27 2022-03-17 Dana-Farber Cancer Institute, Inc. ERK5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1

Similar Documents

Publication Publication Date Title
JP2024530495A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13150U (https=)
BY13161U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)
BY13175U (https=)